Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
MENLO PARK, Calif., Feb. 07, 2017 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 10:30 AM EST and at the LEERINK Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:30 PM EST.
Audio webcasts of Corium’s presentations may be accessed by visiting “Events & Presentations” in the Investors section of the Company’s website at www.coriumgroup.com. The webcasts will be archived on the Corium website for two weeks following the presentations.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact: SMP Communications Susan M. Pietropaolo [email protected] (201) 923-2049
